Host-transcriptomics maps MPOX biology and narrows the search for treatment
MPOX is no longer framed as a localized neglected tropical disease. Its broader spread has turned the infection into a global clinical concern, and the lack of an approved antiviral continues to leave a treatment gap that vaccines alone cannot close. In that setting, host-transcriptomics offers a useful way to look beyond the virus itself and interrogate the host pathways the infection disrupts.
This analysis integrated three transcriptomic datasets and identified 166 common host differentially expressed genes between MPOX patients and control groups. Of those, 75 were upregulated and 91 were downregulated. The pattern matters because host gene expression often reflects the inflammatory, structural, and immune responses a virus co-opts during infection, rather than only the presence of viral material. In MPOX, where access to preventive vaccination remains uneven and many patients may present before vaccination can help, host-directed insights can shape both diagnostic thinking and drug repurposing strategies.
Six host key genes emerged from the interaction network
Protein-protein interaction analysis narrowed the field to six top-ranked host key genes: ALB, HSP90AA1, CDH1, PTPRC, IGF1, and ABL1. These genes were treated as potential MPOX-causing genes within the study framework because of their centrality in the network analysis.
The biology behind those signals is plausible. HSP90AA1 encodes a heat shock protein involved in protein folding and cellular stress responses, a pathway viruses frequently exploit to sustain replication and evade stress-induced shutdown. PTPRC, a marker of leukocyte signaling, points toward immune activation and cellular communication within infected tissue. CDH1 links to epithelial integrity, an especially relevant theme in a virus that causes skin and mucosal disease. ABL1 and IGF1 add signaling and growth-regulatory dimensions, while ALB may reflect systemic host-state changes captured in the transcriptomic signal.
A single interaction hub can be more revealing than a long gene list.
Functional enrichment points to immune, structural, and signaling disruption
Functional enrichment analysis extended the signal from individual genes to higher-order biology. The host key genes mapped to biological processes, molecular functions, cellular components, and KEGG pathways that collectively describe how MPOX perturbs the host environment. Rather than a single linear mechanism, the data suggest a networked disease process involving immune regulation, protein handling, cell adhesion, and intracellular signaling.
Transcription factor and miRNA regulatory network analysis added another layer of control biology. These regulators can alter whether host responses are amplified, delayed, or suppressed, which is clinically relevant in a viral infection where immune timing influences symptom burden, tissue injury, and recovery. A transcriptomic approach cannot prove causality, but it can identify which host programs deserve experimental attention. For MPOX, that means the disease may be shaped not only by viral entry and replication, but also by how host cells regulate stress responses, adhesion, and immune signaling after infection begins.
Docking and simulation favored five repurposable antiviral candidates
The therapeutic portion of the analysis screened candidate drugs against the prioritized host-associated targets and reporting five molecules with the strongest overall profile: Tecovirimat, Beclabuvir, Maraviroc, Raltegravir, and Brincidofovir. The repurposing logic is attractive because drug redevelopment from scratch is slow, while an outbreak-linked disease rewards agents that already have known pharmacology.
Docking analysis suggested favorable binding across the top candidates, and ADME/T plus drug-likeness assessments supported acceptable pharmacokinetic profiles. Those measures do not establish efficacy in patients, but they help determine whether a candidate has a credible path from computational screening to laboratory testing. In a viral illness with no approved treatment, a repurposing shortlist with favorable disposition characteristics is a practical starting point for wet-lab validation.
Three complexes received 100 ns molecular dynamics simulation: ALB-Tecovirimat, CDH1-Maraviroc, and PPARG-Beclabuvir. The simulations showed strong binding stability, with support from RMSD, RMSF, and MM-GBSA results. Stable behavior over time strengthens the argument that these pairs are not fleeting docking artifacts, though they still remain computational predictions rather than clinical proof. Of the named compounds, Tecovirimat and Brincidofovir are especially relevant to MPOX drug discussions because both already sit closer to the antiviral space than many repurposed candidates used in purely exploratory pipelines.
What the transcriptomic signal can and cannot tell clinicians
This study provides a structured molecular map of MPOX host response and a shortlist of repurposable compounds that may merit further testing. It also clarifies a central limitation: computational prioritization cannot substitute for biological verification. The identified host genes need confirmation in wet-lab systems, and the candidate drugs require evidence that the predicted binding relationships translate into meaningful antiviral or host-modulating activity in cells and, eventually, in patients.
The work is still clinically useful because it narrows a crowded search space. Instead of approaching MPOX as an undefined viral syndrome, the analysis frames it as a disease with measurable host transcriptional disruption, identifiable network hubs, and testable therapeutic hypotheses. For clinicians, the practical implication is straightforward: MPOX drug development can move faster when it is anchored to the host biology already visible in patient-derived datasets.
The unanswered step is experimental validation. Without it, the gene signals remain mechanistic hypotheses and the five drug candidates remain candidates, not treatments.